New drug HY6725 enters first human safety tests
NCT ID NCT07262281
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing an experimental drug called HY6725 in 74 healthy adults to see if it is safe and how the body processes it. Participants receive either the drug or a placebo as a single injection or two injections one month apart. The study does not aim to treat any disease, but to gather essential safety and dosing information for future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HY6725 (an experimental biologic injection)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nucleus Network Pty Ltd.
RECRUITINGMelbourne, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test